Funding Opportunity PAR-23-087 from the NIH Guide for Grants and Contracts. The overall goal of this initiative is to identify neurophysiological measures potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the development of more effective treatments for mental disorders.

Notice NOT-HS-23-007 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-105 from the NIH Guide for Grants and Contracts. Reissue of PAR-19-189. The purpose of this funding announcement is to encourage pilot research that is not an immediate precursor to testing a service intervention but is consistent with NIMH priorities for services research. While NIMH now requires use of an experimental therapeutics model for all intervention studies, there is recognition that some mission-relevant areas of services research do not involve clinical trials.

Funding Opportunity PAR-23-104 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage research applications to develop and pilot test the effectiveness and implementation of family navigator models designed to promote early access, engagement and coordination of mental health treatment and services for children and adolescents who are experiencing early symptoms of mental health problems. For the purposes of this FOA, NIMH defines a family navigator model as a health care professional or paraprofessional whose role is to deploy a set of strategies designed to rapidly engage youth and families in needed treatment and services, work closely with the family and other involved treatment and service providers to optimize care and monitor the trajectory of mental health symptoms and outcomes over time. Applicants are encouraged to develop and pilot test the navigator models ability to promote early access, engagement and coordination of mental health treatment and services for children and adolescents as soon as symptoms are detected. Of interest are navigator models that coordinate needed care strategies, determine the personalized match to the level of needed service amount, frequency and intensity, and harness novel technologies to track and monitor the trajectory of clinical, functional and behavioral progress toward achieving intended services outcomes.This FOA is published in parallel to a companion R01 (Currently Temp-11229)

Funding Opportunity PAR-23-103 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-20-401.This Funding Opportunity Announcement (FOA) supports pilot work for subsequent studies testing the effectiveness of strategies to deliver evidence-based mental health services, treatment interventions, and/or preventive interventions (EBPs) in low-resource mental health specialty and non-specialty settings within the United States. The FOA targets settings where EBPs are not currently delivered or delivered with fidelity, such that there are disparities in mental health and related functional outcomes (e.g., employment, educational attainment, stable housing, integration in the community, treatment of comorbid substance use disorders, etc.) for the population(s) served. Implementation strategies should identify and use innovative approaches to remediate barriers to provision, receipt, and/or benefit from EBPs and generate new information about factors integral to achieving equity in mental health outcomes for underserved populations.

Funding Opportunity PAR-23-102 from the NIH Guide for Grants and Contracts. Reissue of RFA-MH-21-106 The purpose of this FOA is to advance translational research to better understand the emergence and worsening of mood and psychotic disorders (e.g., perimenopausal depression (PMD), generalized anxiety disorder, bipolar disorder and schizophrenia) during the menopause transition (MT) in an effort to identity targets for future development of novel treatment interventions. This funding opportunity aims to advance novel and innovative translational research to better comprehend the underlying neurobiological and behavioral mechanisms of mood and psychosis disorders and related symptoms during MT. This funding opportunity also encourages interdisciplinary researchers to collaborate on studies of mood and psychosis during the MT. Aspects of mood and psychosis disorders that are of interest include: classic depressive symptoms in combination with menopause symptoms (e.g., hot flashes, night sweats, sleep disturbance) and psychological challenges, the role of reproductive steroids in the regulation of mood and behavior during the MT, diagnosis of mood and psychosis symptoms at menopausal stage, investigation of co-occurring psychiatric and menopause symptoms, appreciation of psychosocial factors common in midlife, and differential diagnoses. Review criteria will focus on the comprehensiveness of the neurobiology and mechanisms of action underlying mood and psychosis symptoms and hypothesis-driven work.

Funding Opportunity PAR-23-101 from the NIH Guide for Grants and Contracts. Reissue of RFA-20-351.The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue invasive neural recording studies focused on mental health-relevant questions. Invasive neural recordings provide an unparalleled window into the human brain to explore the neural circuitry and neural dynamics underlying complex moods, emotions, cognitive functions, and behaviors with high spatial and temporal resolution. Additionally, the ability to stimulate, via the same electrodes, allows for direct causal tests by modulating network dynamics. This funding opportunity aims to target a gap in the scientific knowledge of neural circuit function related to mental health disorders. Researchers should target specific questions suited to invasive recording modalities that have high translational potential. Development of new technologies and therapies are outside the scope of this FOA.

Notice NOT-OD-23-059 from the NIH Guide for Grants and Contracts

Notice NOT-DA-23-015 from the NIH Guide for Grants and Contracts

Notice NOT-CA-23-015 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-084 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated clinical trials requiring an extended project period of 6 or 7 years. The trials can be any phase, must be hypothesis-driven, and related to the research mission of the participating IC. Consultation with IC staff is strongly encouraged prior to the submission of the clinical trial implementation application. This FOA is not intended for support of clinical trials that do not require an extended project period of 6 or 7 years.

Funding Opportunity RFA-MH-23-170 from the NIH Guide for Grants and Contracts. The proposed FOA would solicit applications focused on enhancing the potency of established adolescent mental health treatments through the use of developmentally informed and theoretically grounded JITAIs. While JITAIs could be applied to established interventions across the lifespan, we propose focusing specifically on adolescence - a developmental period characterized by heightened risk for new onset or worsening mental illness, poor engagement with face-to-face interventions, and peak engagement with technology. JITAIs have the potential to capitalize on adolescents near ubiquitous use of technology to facilitate symptom reduction and behavior change by providing content via an intrinsically motivating platform, facilitating skills practice in ecologically-valid contexts, tailoring the intervention to match the adolescents needs and preferences, providing in-the-moment feedback and reinforcement, and scaffolding adolescents in real time to mitigate impairments. Recent technological advancements have greatly improved the feasibility of delivering JITAIs, and these interventions have shown promise in a variety of health and addiction domains. Yet, no studies of JITAIs for adolescent mental disorders have been published to date, highlighting the need for research in this emerging area of intervention science.

Funding Opportunity PAR-23-076 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) is to provide support for research Centers that (1) conduct drug abuse and addiction research in any area of NIDAs mission, (2) have outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to drug abuse research communities, educational organizations, the general public, and policy makers in the NIDA research fields. It is expected that a Center will transform knowledge in the sciences it is studying. Incremental work should not be the focus of Center activities; rather, new and creative directions are required. The P50 Center of Excellence is expected to foster the career development and mentoring of new investigators who would be given meaningful roles to play in the Center projects. A goal of this program is to create NIDA Centers that are national community resources for furthering drug abuse research by sharing their findings, their data, and their resources as appropriate for researchers to use and build upon and to advance research in this field.

Notice NOT-NS-23-057 from the NIH Guide for Grants and Contracts

Notice NOT-OD-23-056 from the NIH Guide for Grants and Contracts

Notice NOT-DK-23-008 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-23-074 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to phenotype and/or perform research on embryonic lethal knockout (KO) mouse strains being generated through the International Mouse Phenotyping Consortium (IMPC) of which the NIH Knockout Mouse Phenotyping Program (KOMP2) is a member. The mission of IMPC is to generate a comprehensive catalogue of mammalian gene function that will provide the foundation for functional analyses of human genetic variation. The current (July 19, 2022) IMPC data release includes phenotypic data for 8260 knockout genes. Overall, the IMPC hopes to generate a null mutant and undertake broad-based phenotyping for every gene in the mouse genome. About 30% of these strains are expected to be either embryonic or perinatal lethal, or subviable. However, a large portion of homozygous lethal mutations are expected to have viable heterozygous phenotypes. The scientific community has the unique opportunity to leverage these mouse strains while they are being created and bred as part of the IMPC adult mouse phenotyping effort to perform additional in-depth phenotyping and research.

Notice NOT-NS-23-046 from the NIH Guide for Grants and Contracts

Notice NOT-HS-23-006 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-AG-24-001 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications from institutions proposing to develop, or renew, an Alzheimer's Disease Research Center (ADRC). The National Institute on Aging (NIA) funds ADRCs at major medical institutions across the United States. NIA-funded ADRCs serve as a national resource for research related to Alzheimers disease (AD) and AD-related dementias (ADRD). Additionally, ADRCs work to translate research advances into improved diagnosis and care, as well as find ways to treat, and possibly prevent, AD/ADRD. Lastly, ADRCs collaborate and coordinate their research efforts with other programs and investigators funded by the National Institutes of Health (NIH).